Can-Fite BioPharma (NYSE:CANF) Research Coverage Started at StockNews.com

Posted by Anthony Miller on May 4th, 2024

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a report issued on Tuesday morning. The firm issued a hold rating on the stock.

Can-Fite BioPharma Trading Down 0.5 %

CANF opened at $2.02 on Tuesday. The stock’s 50-day moving average price is $2.15 and its 200 day moving average price is $2.10. Can-Fite BioPharma has a 12-month low of $1.81 and a 12-month high of $3.33. The firm has a market cap of $7.15 million, a price-to-earnings ratio of -1.13 and a beta of 1.58.

Can-Fite BioPharma (NYSE:CANF – Get Free Report) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. The business had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.20 million. On average, research analysts forecast that Can-Fite BioPharma will post -0.03 earnings per share for the current year.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. Schechter Investment Advisors LLC purchased a new position in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned about 0.57% of Can-Fite BioPharma as of its most recent SEC filing. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.